- Home
- IMNN vs EDSA Comparison
IMNN vs EDSA Comparison
Compare IMNN & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNN
- EDSA
- Stock Information
- Founded
- IMNN 1982
- EDSA 2015
- Country
- IMNN United States
- EDSA Canada
- Employees
- IMNN N/A
- EDSA N/A
- Industry
- IMNN Biotechnology: Pharmaceutical Preparations
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- IMNN Health Care
- EDSA Health Care
- Exchange
- IMNN Nasdaq
- EDSA Nasdaq
- Market Cap
- IMNN 12.2M
- EDSA 6.1M
- IPO Year
- IMNN 1985
- EDSA N/A
- Fundamental
- Price
- IMNN $0.83
- EDSA $1.73
- Analyst Decision
- IMNN Strong Buy
- EDSA Strong Buy
- Analyst Count
- IMNN 2
- EDSA 1
- Target Price
- IMNN $20.50
- EDSA $21.00
- AVG Volume (30 Days)
- IMNN 395.1K
- EDSA 30.8K
- Earning Date
- IMNN 11-07-2024
- EDSA 02-07-2025
- Dividend Yield
- IMNN N/A
- EDSA N/A
- EPS Growth
- IMNN N/A
- EDSA N/A
- EPS
- IMNN N/A
- EDSA N/A
- Revenue
- IMNN N/A
- EDSA N/A
- Revenue This Year
- IMNN N/A
- EDSA N/A
- Revenue Next Year
- IMNN N/A
- EDSA N/A
- P/E Ratio
- IMNN N/A
- EDSA N/A
- Revenue Growth
- IMNN N/A
- EDSA N/A
- 52 Week Low
- IMNN $0.48
- EDSA $1.55
- 52 Week High
- IMNN $3.65
- EDSA $5.99
- Technical
- Relative Strength Index (RSI)
- IMNN 47.27
- EDSA 31.51
- Support Level
- IMNN $0.80
- EDSA $1.73
- Resistance Level
- IMNN $0.88
- EDSA $1.99
- Average True Range (ATR)
- IMNN 0.05
- EDSA 0.19
- MACD
- IMNN 0.00
- EDSA 0.02
- Stochastic Oscillator
- IMNN 25.00
- EDSA 18.00
About IMNN Imunon Inc.
Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body's immune system. It is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.